Fisher Asset Management LLC Buys 106,912 Shares of Exelixis, Inc. $EXEL

Fisher Asset Management LLC lifted its stake in shares of Exelixis, Inc. (NASDAQ:EXEL) by 228.4% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 153,724 shares of the biotechnology company’s stock after acquiring an additional 106,912 shares during the quarter. Fisher Asset Management LLC’s holdings in Exelixis were worth $6,738,000 as of its most recent filing with the SEC.

Several other large investors also recently made changes to their positions in the stock. RHS Financial LLC boosted its stake in shares of Exelixis by 2.4% during the 4th quarter. RHS Financial LLC now owns 12,619 shares of the biotechnology company’s stock worth $553,000 after acquiring an additional 293 shares in the last quarter. Cim LLC lifted its position in shares of Exelixis by 0.9% during the 3rd quarter. Cim LLC now owns 35,397 shares of the biotechnology company’s stock worth $1,462,000 after purchasing an additional 305 shares during the last quarter. EverSource Wealth Advisors LLC lifted its position in shares of Exelixis by 5.1% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 7,919 shares of the biotechnology company’s stock worth $327,000 after purchasing an additional 384 shares during the last quarter. North Star Asset Management Inc. lifted its position in shares of Exelixis by 0.7% during the 3rd quarter. North Star Asset Management Inc. now owns 57,550 shares of the biotechnology company’s stock worth $2,377,000 after purchasing an additional 400 shares during the last quarter. Finally, Spire Wealth Management lifted its position in shares of Exelixis by 4.5% during the 4th quarter. Spire Wealth Management now owns 9,643 shares of the biotechnology company’s stock worth $423,000 after purchasing an additional 416 shares during the last quarter. Institutional investors own 85.27% of the company’s stock.

Trending Headlines about Exelixis

Here are the key news stories impacting Exelixis this week:

• Positive Sentiment: Zacks Research raised its Q2 2026 EPS estimate for Exelixis to $0.75 from $0.72, reinforcing expectations that the company can continue delivering solid profitability.
• Positive Sentiment: Exelixis is set to participate in upcoming June investor conferences, which can help keep attention on the stock and provide new updates on pipeline and commercial progress. Article Title
• Positive Sentiment: A recent article argued that profitable, cash-generative biotech names like Exelixis may benefit as investors rotate away from expensive growth stocks and toward defensive healthcare ideas. Article Title
• Positive Sentiment: At the company’s annual meeting, investors backed the board, equity plan, and executive pay, signaling governance support and reducing uncertainty. Article Title
• Neutral Sentiment: Exelixis presented at Bernstein’s Strategic Decisions Conference, which keeps the company visible to institutional investors but did not include any major new operating update. Article Title
• Neutral Sentiment: A short-interest report showed essentially no short interest in Exelixis, suggesting limited bearish positioning but not a meaningful catalyst on its own.
• Negative Sentiment: EVP Dana Aftab sold 43,451 shares at an average price of $50.35, a disclosed insider sale that can weigh on sentiment even though the executive still holds a large position. Article Title

Exelixis Stock Up 2.8%

Exelixis stock opened at $51.45 on Friday. The business has a 50 day moving average price of $45.83 and a two-hundred day moving average price of $44.18. The stock has a market cap of $12.93 billion, a price-to-earnings ratio of 17.09, a price-to-earnings-growth ratio of 1.06 and a beta of 0.38. Exelixis, Inc. has a 12 month low of $33.76 and a 12 month high of $52.96.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported $0.87 EPS for the quarter, beating the consensus estimate of $0.75 by $0.12. The firm had revenue of $610.81 million during the quarter, compared to analysts’ expectations of $607.51 million. Exelixis had a return on equity of 39.89% and a net margin of 35.08%.The company’s revenue for the quarter was up 10.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.55 EPS. On average, analysts expect that Exelixis, Inc. will post 3.15 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts recently weighed in on EXEL shares. Wall Street Zen raised Exelixis from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. Truist Financial raised Exelixis to a “strong-buy” rating in a research report on Monday, April 27th. Stifel Nicolaus boosted their price objective on Exelixis from $44.00 to $47.00 and gave the stock a “hold” rating in a research report on Wednesday, May 6th. Barclays boosted their price objective on Exelixis from $44.00 to $45.00 and gave the stock an “equal weight” rating in a research report on Monday, April 20th. Finally, Weiss Ratings reissued a “buy (b)” rating on shares of Exelixis in a research report on Tuesday, May 19th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, eleven have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, Exelixis currently has a consensus rating of “Hold” and an average price target of $47.35.

Insider Transactions at Exelixis

In other Exelixis news, EVP Dana Aftab sold 43,451 shares of the company’s stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $50.35, for a total value of $2,187,757.85. Following the completion of the transaction, the executive vice president owned 594,741 shares of the company’s stock, valued at $29,945,209.35. This represents a 6.81% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Christopher J. Senner sold 34,901 shares of the company’s stock in a transaction that occurred on Monday, May 18th. The shares were sold at an average price of $50.00, for a total value of $1,745,050.00. Following the completion of the transaction, the chief financial officer directly owned 952,317 shares of the company’s stock, valued at approximately $47,615,850. This trade represents a 3.54% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 205,433 shares of company stock worth $9,930,259. 2.60% of the stock is currently owned by company insiders.

About Exelixis

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.